Molecular basis of invasion in breast cancer

Cellular and Molecular Life Sciences

Volumn 64, Issue 24, 2007, Pages 3201-3218

  McSherry, E A ^a   Donatello, S ^a   Hopkins, A M ^a   McDonnell, S ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast cancer; Cell adhesion; ECM (extracellular matrix); EMT (epithelial mesenchymal transition); Invasion; Microenvironment; Migration

Indexed keywords

METALLOPROTEINASE;

BIOLOGICAL MODEL; BREAST TUMOR; CANCER INVASION; CELL ADHESION; CELL MOTION; CLASSIFICATION; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; TUMOR ESCAPE;

BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METALLOPROTEASES; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR ESCAPE;

EID: 39749147839     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-007-7388-0     Document Type: Article

References (163)

1. Bray, F., Sankila, R., Ferlay, J. and Parkin, D. M. (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer 38, 99-166.
2. Baselga, J. (2001) Phase I and II clinical trials of trastuzumab. Ann. Oncol. 12 Suppl. 1, S49-55.
3. Baselga, J., Perez, E. A., Pienkowski, T. and Bell, R. (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl. 1, 4-12.
4. Beckmann, M.W., Niederacher, D., Schnurch, H. G., Gusterson, B. A. and Bender, H. G. (1997) Multistep carcinogenesis of breast cancer and tumour heterogeneity. J. Mol. Med. 75, 429-439.
5. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A. et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752.
6. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874.
7. Sorlie, T. (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer 40, 2667-2675.
8. Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B. et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98, 262-272.
9. van't Veer, L. J. Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
10. van de Vijver, M. J. He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C. Marton, M. J. et al. (2002)Agene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009.
11. Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., d'Assignies, M. S., Bergh, J., Lidereau, R., Ellis, P. et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98, 1183-1192.
12. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., Massague, J. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.
13. Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., Guise, T. A. and Massague, J. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
14. Eckhardt, B. L., Parker, B. S., van Laar, R. K., Restall, C. M., Natoli, A. L., Tavaria, M. D., Stanley, K. L., Sloan, E. K., Moseley, J. M. and Anderson, R. L. (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellularmatrix. Mol. Cancer Res. 3, 1-13.
15. Ramaswamy, S., Ross, K. N., Lander, E. S. and Golub, T. R. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54.
16. Fidler, I. J. (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458.
17. Abba, M. C., Drake, J. A., Hawkins, K. A., Hu, Y., Sun, H., Notcovich, C., Gaddis, S., Sahin, A., Baggerly, K. and Aldaz, C. M. (2004) Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 6, R499-513.
18. Ma, X. J., Salunga, R., Tuggle, J. T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B. M. et al. (2003) Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. USA 100, 5974-5979.
19. Nishidate, T., Katagiri, T., Lin, M. L., Mano, Y., Miki, Y., Kasumi, F., Yoshimoto, M., Tsunoda, T., Hirata, K. and Nakamura, Y. (2004) Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int. J. Oncol. 25, 797-819.
20. Porter, D. A., Krop, I.E., Nasser, S., Sgroi, D., Kaelin, C. M., Marks, J. R., Riggins, G. and Polyak, K. (2001) A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 61, 5697-702.
21. Schuetz, C. S., Bonin, M., Clare, S. E., Nieselt, K., Sotlar, K., Walter, M., Fehm, T., Solomayer, E., Riess, O., Wallwiener, D. et al. (2006) Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture micro- dissection and oligonucleotide microarray analysis. Cancer Res. 66, 5278-5286.
22. Wang, W., Goswami, S., Lapidus, K., Wells, A. L., Wyckoff, J. B., Sahai, E., Singer, R. H., Segall, J. E. and Condeelis, J. S. (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 64, 8585-8594.
23. Fenteany, G., Janmey, P. A. and Stossel, T. P. (2000) Signaling pathways and cell mechanics involved in wound closure by epithelial cell sheets. Curr. Biol. 10, 831-838.
24. Lauffenburger, D. A. and Horwitz, A. F. (1996) Cell migration: a physically integrated molecular process. Cell 84, 359-369.
25. Webb, D. J., Parsons, J. T. and Horwitz, A. F. (2002) Adhesion assembly, disassembly and turnover in migrating cells-over and over and over again. Nat. Cell Biol. 4, E97-100.
26. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D. and Hall, A. (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401-410.
27. Nobes, C. D. and Hall, A. (1995) Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81, 53-62.
28. Kozma, R., Ahmed, S., Best, A. and Lim, L. (1995) The Rasrelated protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol. Cell. Biol. 15, 1942-1952.
29. Lorenz, M., Yamaguchi, H., Wang, Y., Singer, R. H. and Condeelis, J. (2004) Imaging sites of N-wasp activity in lamellipodia and invadopodia of carcinoma cells. Curr. Biol. 14, 697-703.
30. Zucker, S., Cao, J. and Chen, W. T. (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650.
31. Hamano, Y. and Kalluri, R. (2005) Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun. 333, 292-298.
32. Slamon, D. J. Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. and Ullrich, A. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
33. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A. et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671.
34. Alper, O., Bergmann-Leitner, E. S., Bennett, T. A., Hacker, N. F., Stromberg, K. and Stetler-Stevenson, W. G. (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J. Natl. Cancer Inst. 93, 1375-1384.
35. Elliott, B. E., Hung, W. L., Boag, A. H. andTuck, A. B. (2002) The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can. J. Physiol. Pharmacol. 80, 91-102.
36. Royal, I., Lamarche-Vane, N., Lamorte, L., Kaibuchi, K. and Park, M. (2000) Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol. Biol. Cell 11, 1709-1725.
37. Hopkins, A. M. Bruewer, M., Brown, G. T., Pineda, A. A., Ha, J. J., Winfree, L. M., Walsh, S. V., Babbin, B. A. and Nusrat, A. (2004) Epithelial cell spreading induced by hepatocyte growth factor influences paxillin protein synthesis and posttranslational modification. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G886-898.
38. Bell, C. D. and Waizbard, E. (1986) Variability of cell size in primary and metastatic human breast carcinoma. Invasion Metastasis 6, 11-20.
39. Friedl, P. and Wolf, K. (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3, 362-374.
40. Wyckoff, J. B., Pinner, S. E., Gschmeissner, S., Condeelis, J. S. and Sahai, E. (2006) ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol. 16, 1515-1523.
41. Wolf, K. Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Brocker, E. B. and Friedl, P. (2003) Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 160, 267-277.
42. Sahai, E. and Marshall, C. J. (2003) Differing modes of tumour cell invasion have distinct requirements for Rho/ ROCKsignalling and extracellular proteolysis.Nat. Cell Biol. 5, 711-719.
43. Somlyo, A. V., Bradshaw, D., Ramos, S., Murphy, C., Myers, C. E. and Somlyo, A. P. (2000) Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 269, 652-659.
44. Wang, W., Goswami, S., Sahai, E., Wyckoff, J. B., Segall, J. E. and Condeelis, J. S. (2005) Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 15, 138-145.
45. Kalluri, R. and Zeisberg, M. (2006) Fibroblasts in cancer.Nat. Rev. Cancer 6, 392-401.
46. Schor, S. L., Schor, A. M. and Rushton, G. (1988) Fibroblasts from cancer patients display a mixture of both foetal and adult-like phenotypic characteristics. J. Cell Sci. 90 (Pt 3), 401-407.
47. Dvorak, H. F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659.
48. Micke, P. and Ostman, A. (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin. Ther. Targets 9, 1217-1233.
49. Sieweke, M. H., Thompson, N. L., Sporn, M. B. and Bissell, M. J. (1990) Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 248, 1656-1660.
50. Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti- Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A. et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17-32.
51. Heylen, N., Baurain, R., Remacle, C. and Trouet, A. (1998) Effect of MRC-5 fibroblast conditioned medium on breast cancer cell motility and invasion in vitro.Clin. Exp. Metastasis 16, 193-203.
52. Barcellos-Hoff, M. H. and Ravani, S. A. (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260.
53. Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., Richardson, A. and Weinberg, R. A. (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA 101, 4966-4971.
54. Orimo, A. Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L. and Weinberg, R. A. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
55. Gudjonsson, T., Adriance, M. C., Sternlicht, M. D., Petersen, O.W. and Bissell, M. J. (2005) Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J. Mammary Gland Biol. Neoplasia 10, 261-272.
56. Polyak, K. and Hu, M. (2005) Do myoepithelial cells hold the key for breast tumor progression? J. Mammary Gland Biol. Neoplasia 10, 231-247.
57. Adriance, M. C., Inman, J. L., Petersen, O.W. and Bissell, M. J. (2005) Myoepithelial cells: good fences make good neighbors. Breast Cancer Res. 7, 190-197.
58. Gudjonsson, T., Ronnov-Jessen, L., Villadsen, R., Rank, F., Bissell, M. J. and Petersen, O.W. (2002) Normal and tumorderived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. 115, 39-50.
59. Barsky, S. H. (2003) Myoepithelial mRNA expression profiling reveals a common tumor-suppressor phenotype.Exp.Mol. Pathol. 74, 113-122.
60. Porter, D., Lahti-Domenici, J., Keshaviah, A., Bae, Y. K., Argani, P., Marks, J., Richardson, A., Cooper, A., Strausberg, R., Riggins, G. J. et al. (2003) Molecular markers in ductal carcinoma in situ of the breast. Mol. Cancer Res. 1, 362-375.
61. Man, Y. G. and Sang, Q. X. (2004) The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the 'protease-centered' hypothesis. Exp. Cell Res. 301, 103-118.
62. Peyrol, S., Raccurt, M., Gerard, F., Gleyzal, C., Grimaud, J. A. and Sommer, P. (1997) Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am. J. Pathol. 150, 497-507.
63. Stephenson, J. M., Banerjee, S., Saxena, N. K., Cherian, R. and Banerjee, S. K. (2002) Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int. J. Cancer 101, 409-414.
64. Hu, M., Yao, J., Cai, L., Bachman, K. E., van den Brule, F., Velculescu, V. and Polyak, K. (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37, 899-905.
65. Nathan, C. (2002) Points of control in inflammation. Nature 420, 846-852.
66. Gouon-Evans, V., Rothenberg, M. E. and Pollard, J.W. (2000) Postnatal mammary gland development requires macrophages and eosinophils. Development 127, 2269-2282.
67. Pollard, J.W. (2004) Tumour-educated macrophages promote tumour progression andmetastasis. Nat. Rev. Cancer 4, 71-78.
68. Bingle, L., Brown, N. J. and Lewis, C. E. (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265.
69. Leek, R. D., Hunt, N. C., Landers, R. J., Lewis, C. E., Royds, J. A. and Harris, A. L. (2000) Macrophage infiltration is associated withVEGFandEGFRexpression in breast cancer. J. Pathol. 190, 430-436.
70. Boudreau, N. and Myers, C. (2003) Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 5, 140-146.
71. Ueno, T., Toi, M., Saji, H., Muta, M., Bando, H., Kuroi, K., Koike, M., Inadera, H. and Matsushima, K. (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289.
72. Balkwill, F., Charles, K. A. and Mantovani, A. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217.
73. Lin, E. Y., Gouon-Evans, V., Nguyen, A. V. and Pollard, J. W. (2002) The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 7, 147-162.
74. Goswami, S., Sahai, E., Wyckoff, J. B., Cammer, M., Cox, D., Pixley, F. J., Stanley, E. R., Segall, J. E. and Condeelis, J. S. (2005) Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65, 5278-5283.
75. Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., Graf, T., Pollard, J.W., Segall, J. and Condeelis, J. (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64, 7022-7029.
76. Sahai, E. (2005) Mechanisms of cancer cell invasion. Curr. Opin. Genet. Dev. 15, 87-96.
77. Polette, M., Nawrocki-Raby, B., Gilles, C., Clavel, C. and Birembaut, P. (2004) Tumour invasion and matrix metalloproteinases. Crit. Rev. Oncol. Hematol. 49, 179-186.
78. Boudreau, N. J. and Jones, P. L. (1999) Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 339 (Pt 3), 481-488.
79. Lukashev, M. E. and Werb, Z. (1998) ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8, 437-441.
80. Shi, Y. E., Torri, J., Yieh, L., Wellstein, A., Lippman, M. E. and Dickson, R. B. (1993) Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 53, 1409-1415.
81. Nagase, H., Visse, R. and Murphy, G. (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573.
82. Egeblad, M. andWerb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
83. Parsons, S. L., Watson, S. A., Brown, P. D., Collins, H. M. and Steele, R. J. (1997) Matrix metalloproteinases. Br. J. Surg. 84, 160-166.
84. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L. and Matrisian, L. M. (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 94, 1402-1407.
85. Poulsom, R., Hanby, A. M., Pignatelli, M., Jeffery, R. E., Longcroft, J. M., Rogers, L. and Stamp, G.W. (1993) Expression of gelatinaseAand TIMP-2mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J. Clin. Pathol. 46, 429-436.
86. Daidone, M. G., Silvestrini, R., D'Errico, A., Di Fronzo, G., Benini, E., Mancini, A. M., Garbisa, S., Liotta, L. A. and Grigioni, W. F. (1991) Laminin receptors, collagenase IVand prognosis in node-negative breast cancers. Int. J. Cancer 48, 529-532.
87. Hoyhtya, M., Hujanen, E., Turpeenniemi-Hujanen, T., Thorgeirsson, U., Liotta, L. A. and Tryggvason, K. (1990) Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int. J. Cancer 46, 282-286.
88. Okada, A., Bellocq, J. P., Rouyer, N., Chenard, M. P., Rio, M. C., Chambon, P. and Basset, P. (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 92, 2730-2734.
89. Scorilas, A., Karameris, A., Arnogiannaki, N., Ardavanis, A., Bassilopoulos, P., Trangas, T. and Talieri, M. (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 84, 1488-1496.
90. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C. and Chambon, P. (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348, 699-704.
91. Chambers, A. F. and Matrisian, L. M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260-1270.
92. Ravanti, L. and Kahari, V. M. (2000) Matrix metalloproteinases in wound repair (review) Int. J. Mol. Med. 6, 391-407.
93. Clemmons, D. R. (1998) Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol. Cell Endocrinol. 140, 19-24.
94. Lee, Y. J. and Streuli, C. H. (1999) Extracellular matrix selectively modulates the response of mammary epithelial cells to different soluble signaling ligands. J. Biol. Chem. 274, 22401-22408.
95. Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G. and Quaranta, V. (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 225-228.
96. Xu, J., Rodriguez, D., Petitclerc, E., Kim, J. J., Hangai, M., Moon, Y. S., Davis, G. E. and Brooks, P. C. (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154, 1069-1079.
97. Jones, J. L. and Walker, R. A. (1997) Control of matrix metalloproteinase activity in cancer. J. Pathol. 183, 377-379.
98. Whittaker, M., Floyd, C. D., Brown, P. and Gearing, A. J. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735-2776.
99. Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C. and Buckels, J. A. (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447-3455.
100. Coussens, L. M., Fingleton, B. and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
101. Wynn, R. L. (1999) Latest FDA approvals for dentistry. Gen. Dent. 47, 19-22.
102. Luo, B.-H., Carman, C. V. and Springer, T. A. (2007) Structural basis of integrin regulation and signaling. Ann. Rev. Immunol. 25, 619-647.
103. Friedrichs, K., Ruiz, P., Franke, F., Gille, I., Terpe, H. J. and Imhof, B. A. (1995) High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res. 55, 901-906.
104. Yoon, S. O., Shin, S. and Lipscomb, E. A. (2006) A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ ErbB2 signaling. Cancer Res. 66, 2732-2739.
105. Lipscomb, E. A., Simpson, K. J., Lyle, S. R., Ring, J. E., Dugan, A. S. and Mercurio, A. M. (2005) The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res. 65, 10970-10976.
106. Chung, J. and Mercurio, A. M. (2004) Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol. Cells 17, 203-209.
107. Chung, J., Yoon, S., Datta, K., Bachelder, R. E. and Mercurio, A. M. (2004) Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells. Cancer Res. 64, 4711-4716.
108. Yoon, S. O., Shin, S. and Mercurio, A. M. (2005) Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer Res. 65, 2761-2769.
109. Weaver, V. M., Petersen, O.W., Wang, F., Larabell, C. A., Briand, P., Damsky, C. and Bissell, M. J. (1997) Reversion of the malignant phenotype of human breast cells in threedimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245.
110. Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J. and Bissell, M. J. (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526-1535.
111. Lopez, J. I., Camenisch, T. D., Stevens, M. V., Sands, B. J., McDonald, J. and Schroeder, J. A. (2005) CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res. 65, 6755-6763.
112. Diaz, L. K., Zhou, X., Wright, E. T., Cristofanilli, M., Smith, T., Yang, Y., Sneige, N., Sahin, A. and Gilcrease, M. Z. (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin. Cancer Res. 11, 3309-3314.
113. Dall, P., Heider, K. H., Sinn, H. P., Skroch-Angel, P., Adolf, G., Kaufmann, M., Herrlich, P. and Ponta, H. (1995) Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int. J. Cancer 60, 471-477.
114. Iida, N. and Bourguignon, L. Y. (1995) New CD44 splice variants associated with human breast cancers. J. Cell Physiol. 162, 127-133.
115. Kalish, E. D., Iida, N., Moffat, F. L. and Bourguignon, L. Y. (1999) A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression. Front. Biosci. 4, A1-8.
116. Kaufmann, M., Heider, K. H., Sinn, H. P., von Minckwitz, G., Ponta, H. and Herrlich, P. (1995) CD44 isoforms in prognosis of breast cancer. Lancet 346, 502.
117. Sy, M. S., Mori, H. and Liu, D. (1997) CD44 as a marker in human cancers. Curr. Opin. Oncol. 9, 108-112.
118. Bourguignon, L. Y., Gunja-Smith, Z., Iida, N., Zhu, H. B., Young, L. J., Muller, W. J. and Cardiff, R. D. (1998) CD44v(3, 8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell Physiol. 176, 206-215.
119. Auvinen, P., Tammi, R., Tammi, M., Johansson, R. and Kosma, V. M. (2005) Expression ofCD44 s, CD44 v 3 andCD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 47, 420-428.
120. Liu, Y. J., Yan, P. S., Li, J. and Jia, J. F. (2005) Expression and significance of CD44 s, CD44v6, and nm23 mRNA in human cancer. World J. Gastroenterol. 11, 6601-6606.
121. Ma, W., Deng, Y. and Zhou, L. (2005) The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin. Oncol. (R. Coll. Radiol.) 17, 258-263.
122. Feldman, G. J., Mullin, J. M. and Ryan, M. P. (2005) Occludin: structure, function and regulation. Adv. Drug Deliv. Rev. 57, 883-917.
123. Norimasa, S., Masaki, M., Keisuke, K., Makoto, O., Hirotoshi, T., Takashi, K. and Hideki, C. (2003)Tight junctions and human diseases. Medical Electron Microscopy V36, 147.
124. Swisshelm, K., Machl, A., Planitzer, S., Robertson, R., Kubbies, M. and Hosier, S. (1999) SEMP1, a senescenceassociated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily. Gene 226, 285.
125. Tokes, A. M., Kulka, J., Paku, S., Szik, A., Paska, C., Novak, P. K., Szilak, L., Kiss, A., Bogi, K. and Schaff, Z. (2005) Claudin-1, -3 and -4 proteins andmRNAexpression in benign and malignant breast lesions: a research study. Breast Cancer Res 7, R296-305.
126. Kramer, F., White, K., Kubbies, M., Swisshelm, K. andWeber, B. H. (2000) Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum. Genet. 107, 249-256.
127. Hoevel, T., Macek, R., Swisshelm, K. and Kubbies, M. (2004) Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids. Int. J. Cancer 108, 374-383.
128. Kominsky, S. L., Argani, P., Korz, D., Evron, E., Raman, V., Garrett, E., Rein, A., Sauter, G., Kallioniemi, O. P. and Sukumar, S. (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22, 2021-2033.
129. Sauer, T., Pedersen, M. K., Ebeltoft, K. and Naess, O. (2005) Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 16, 193-198.
130. Wu, X., Chen, H., Parker, B., Rubin, E., Zhu, T., Lee, J. S., Argani, P. and Sukumar, S. (2006) HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 66, 9527-9534.
131. Polette, M., Gilles, C., Nawrocki-Raby, B., Lohi, J., Hunziker, W., Foidart, J. M. and Birembaut, P. (2005) Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells. Cancer Res. 65, 7691-7698.
132. Polette, M., Gilles, C., Nawrocki-Raby, B., Lohi, J., Hunziker, W., Foidart, J.-M. and Birembaut, P. (2005) Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells. Cancer Res. 65, 7691-7698.
133. Hoover, K. B., Liao, S. Y. and Bryant, P. J. (1998) Loss of the tight junctionMAGUKZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am. J. Pathol. 153, 1767-1773.
134. Karen A. and Knudsen, M. J.W. (2005) Cadherins and the mammary gland. Journal ofCellularBiochemistry 95, 488-496.
135. Derksen, P. W., Liu, X., Saridin, F., van der Gulden, H., Zevenhoven, J., Evers, B., van Beijnum, J. R., Griffioen, A.W., Vink, J., Krimpenfort, P. et al. (2006) Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437-449.
136. Palacios, J., Sarrio, D., Garcia-Macias, M. C., Bryant, B., Sobel, M. E. and Merino, M. J. (2003) Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod. Pathol. 16, 674.
137. Hazan, R. B., Phillips, G. R., Qiao, R. F., Norton, L. and Aaronson, S. A. (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 148, 779-790.
138. Peralta Soler, A., Knudsen, K. A., Salazar, H., Han, A. C. and Keshgegian, A. A. (1999) P-cadherin expression in breast carcinoma indicates poor survival. Cancer 86, 1263-1272.
139. Paredes, J., Lopes, N., Milanezi, F. and Schmitt, F. C. (2007) Pcadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Archiv. 450, 73-80.
140. Lee, S. W., Reimer, C. L., Campbell, D. B., Cheresh, P., Duda, R. B. and Kocher, O. (1998) H-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo. Carcinogenesis 19, 1157-1159.
141. Fiegl, H., Millinger, S., Goebel, G., Muller-Holzner, E., Marth, C., Laird, P.W. andWidschwendter, M. (2006) Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 66, 29-33.
142. Toyooka, K. O., Toyooka, S., Virmani, A. K., Sathyanarayana, U. G., Euhus, D. M., Gilcrease, M., Minna, J. D. and Gazdar, A. F. (2001) Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61, 4556-4560.
143. Brennan, K. R. and Brown, A. M. (2004) Wnt proteins in mammary development and cancer. J.Mammary Gland Biol. Neoplasia 9, 119-131.
144. Hatsell, S., Rowlands, T., Hiremath, M. and Cowin, P. (2003) Beta-catenin and Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 8, 145-158.
145. Lin, S.-Y., Xia, W., Wang, J. C., Kwong, K. Y., Spohn, B., Wen, Y., Pestell, R. G. and Hung, M.-C. (2000) beta-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 97, 4262-4266.
146. Howe, L. R., Watanabe, O., Leonard, J. and Brown, A. M.C. (2003) Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 63, 1906-1913.
147. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. and Clarke, M. F. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
148. Roh, M. S., Hong, S. H., Jeong, J. S., Kwon, H. C., Kim, M. C., Cho, S. H., Yoon, J. H. and Hwang, T. H. (2004) Gene expression profiling of breast cancers with emphasis of betacatenin regulation. J. Korean Med. Sci. 19, 275-282.
149. Thiery, J. P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442.
150. Vincent-Salomon, A. and Thiery, J. (2003) Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 5, 101-106.
151. Lombaerts, M., van Wezel, T., Philippo, K., Dierssen, J.W., Zimmerman, R. M., Oosting, J., van Eijk, R., Eilers, P. H., van de Water, B., Cornelisse, C. J. and Cleton-Jansen, A. M. (2006) E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-tomesenchymal transition in breast cancer cell lines. Br. J. Cancer 94, 661-671.
152. Birchmeier, W. and Behrens, J. (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta 1198, 11-26.
153. Wheelock, M. J., Soler, A. P. and Knudsen, K. A. (2001) Cadherin junctions in mammary tumors. J. Mammary Gland Biol. Neoplasia 6, 275-285.
154. Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F. and Nieto, M. A. (2000) The transcription factor snail controls epithelialmesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76-83.
155. Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D. and van Roy, F. (2001) The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267-1278.
156. Vandewalle, C., Comijn, J., De Craene, B., Vermassen, P., Bruyneel, E., Andersen, H., Tulchinsky, E., Van Roy, F. and Berx, G. (2005) SIP1/ZEB2 inducesEMTby repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 33, 6566-6578.
157. Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S. and Nakshatri, H. (2006) NF-kappaB represses Ecadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26, 711-724.
158. Kim, J. B., Islam, S., Kim, Y. J., Prudoff, R. S., Sass, K. M., Wheelock, M. J. and Johnson, K. R. (2000) N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J. Cell Biol. 151, 1193-1206.
159. Niemann, C., Brinkmann, V., Spitzer, E., Hartmann, G., Sachs, M., Naundorf, H. and Birchmeier, W. (1998) Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J. Cell Biol. 143, 533-545.
160. Zavadil, J., Bitzer, M., Liang, D., Yang, Y.-C., Massimi, A., Kneitz, S., Piek, E. and Bottinger, E. P. (2001) Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc. Natl. Acad. Sci. USA 98, 6686-6691.
161. Planas-Silva, M. D. and Waltz, P. K. (2006) Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 104, 11-21.
162. Galliher, A. J. and Schiemann, W. P. (2006) beta3 Integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8, R42.
163. Thiery, J. P. and Sleeman, J. P. (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131.